Fundz

Blood-testing startup Helios raised $2.3M in seed funding backed by Y Combinator and Formation VC, using proteomics and AI to predict organ health from a single blood drop.

PRIVATENov 21, 2026

Amount Raised

$2.3 Million

Round Type

Seed

BiotechnologyHealth CareArtificial Intelligence

Investors

Formation VCY Combinator

Description

Helios, a Y Combinator-backed blood-testing startup, raised $2.3 million in seed funding to develop its proteomics and AI platform for predicting organ health and disease risk from a single drop of blood. The company emerged from stealth this week with backing from Y Combinator and Formation VC. Despite comparisons to Theranos from prospective investors, Helios differentiates itself through its use of advanced proteomics technology and artificial intelligence. The company plans to launch its test in 2027.

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Helios that raised within 45 days of this round, from Fundz verified event records.

  • ChronoScale Holdings Corp raised $153M (Series C) on November 18, 2026.
  • Soombit AI raised $9M (Series A) on November 17, 2026.
  • TestDynamics raised $9M (Series A) on November 16, 2026.
  • MedInTech raised $25M (Series C) on November 16, 2026.
  • Boston Medical Sciences raised $35M (Series B) on November 13, 2026.
  • Orakl Oncology raised $34M (Series A) on November 12, 2026.

Who to call at Helios, and when

A new round usually means Helios is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Helios raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Helios, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Helios. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Helios

About

Helios is a Y Combinator-backed blood-testing startup that uses proteomics and AI to predict organ health and future disease risk from a single drop of blood. The company raised $2.3 million in seed funding from investors including Formation VC. Helios plans to launch its test in 2027.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Helios raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Helios's next move

See what Strategic adds

Helios raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.